Captopril-associated "pseudocholangitis'. A case report and review of the literature.
Captopril, a competitive inhibitor of angiotensin-converting enzyme, is widely used in the treatment of hypertension and heart failure. Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects. However, hepatotoxicity is extremely rare. A patient with severe cholestatic jaundice induced by captopril is presented. On admission to the hospital, the patient was diagnosed and treated as having cholangitis. Review of the literature showed similar occurrences in other patients. Patients treated with captopril who develop "atypical cholangitis" should be suspected of having captopril-associated liver damage.
Nissan
A
A
Department of Surgery, Hadassah University Hospital Mount Scopus, Jerusalem, Israel.
Spira
R M
RM
Seror
D
D
Ackerman
Z
Z
D000368:Aged; D002216:Captopril / Q000009:adverse effects*; D002761:Cholangitis / Q000139:chemically induced* / Q000175:diagnosis; D002779:Cholestasis / Q000139:chemically induced*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy
D002216:Captopril